Table 1 The baseline characteristics and regression of patients with sinonasal malignancies (imputed).

From: Development and validation of a clinico-histological factor-based nomogram for survival in sinonasal malignancies

 

All

(n = 5795)

Training set

(n = 4056)

Validation set

(n = 1739)

All variables model

Selected variables model

TR(95%CI)

P

TR(95%CI)

P

Coefficient

Age

Median, IQR

65 0.00

(55.00, 74.00)

65.00

(55.00, 74.60)

64.60

(54.60, 74.20)

0.976

(0.97–0.98)

< 0.001

0.973

(0.97–0.98)

< 0.001

0.02

Sex

Female

2222 (38.3%)

1541 (38.0%)

681 (39.2%)

-

-

-

-

-

Male

3573 (61.7%)

2515 (62.0%)

1058 (60.8%)

0.84

(0.72–0.97)

0.009

0.84

(0.72–0.97)

0.019

0.18

Marriage

Married

3275 (56.5%)

2298 (56.6%)

977 (56.2%)

-

-

-

-

-

Unmarried

2520 (43.5%)

1758 (43.4%)

762 (43.8%)

0.73

(0.62–0.85)

< 0.001

0.74

(0.63–0.86)

< 0.001

0.30

Race

Asian

427 (7.4%)

-

-

-

-

-

-

-

Black

579 (10.0%)

-

-

1.17

(0.84–1.63)

0.345

-

-

-

Other

150 (2.6%)

-

-

1.01

(0.61–1.67)

0.965

-

-

-

White

4639 (80.1%)

-

-

1.149

(0.885–1.491)

0.296

-

-

-

AJCC stage

I

1415 (24.4%)

984 (24.3%)

424 (24.4%)

-

-

-

-

-

II

564 (9.7%)

393 (9.7%)

163 (9.4%)

0.29

(0.20–0.41)

< 0.001

0.29

(0.20–0.41)

< 0.001

1.25

III

1042 (18.0%)

715 (17.6%)

312 (18.0%)

0.15

(0.10–0.21)

< 0.001

0.14

(0.1–0.20)

< 0.001

1.96

IVA

1293 (22.3%)

920 (22.7%)

391 (22.5%)

0.10

(0.07–0.14)

< 0.001

0.09

(0.07–0.13)

< 0.001

2.36

IVB

1099 (19.0%)

772 (19.0%)

335 (19.3%)

0.06

(0.05–0.09)

< 0.001

0.06

(0.04–0.08)

< 0.001

2.83

IVC

382 (6.6%)

272 (6.7%)

113 (6.5%)

0.03

(0.02–0.05)

< 0.001

0.03

(0.02–0.05)

< 0.001

3.46

Site

Ethmoid sinus

473(8.2%)

323 (8.0%)

150 (8.6%)

-

-

-

-

 

Maxillary sinus

1936 (33.4%)

1358 (33.5%)

578 (33.2%)

0.84

(0.65–1.08)

0.175

0.84

(0.65–1.09)

0.192

0.17

Nasal cavity

3386 (58.4%)

2375 (58.6%)

1011 (58.1%)

1.83

(1.41–2.36)

< 0.001

1.85

(1.44–2.39)

< 0.001

0.62

Histology1

AC

353 (6.1%)

248 (6.1%)

108 (6.2%)

-

-

-

-

 

ACC

353 (6.1%)

251 (6.2%)

101 (5.8%)

1.10

(0.70–1.74)

0.682

1.13

(0.72–1.79)

0.600

0.13

Other2,3

989(17.1%)

686 (16.9%)

302 (17.4%)

0.59

(0.40–0.87)

0.008

0.58

(0.39–0.86)

0.006

0.54

PMM

573(9.7%)

394 (9.7%)

179 (10.3%)

0.29

(0.19–0.45)

< 0.01

0.30

(0.20–0.46)

< 0.001

1.20

SCC

3309 (57.1%)

2320 (57.2%)

984 (56.6%)

0.66

(0.46–0.94)

0.022

0.65

(0.46–0.93)

0.018

0.43

UC

218 (3.8%)

156 (3.9%)

65 (3.7%)

0.44

(0.27–0.72)

0.001

0.42

(0.26–0.68)

< 0.001

0.87

Surgery

No

1768 (30.6%)

1230 (30.3%)

538 (30.9%)

-

-

-

-

 

Yes

4027 (69.4%)

2826 (69.7%)

1201 (69.1%)

3.17

(2.71–3.70)

< 0.001

3.26

(2.76–3.77)

< 0.001

1.17

Chemotherapy

No

3914 (67.5%)

-

-

-

-

-

-

-

Yes

1881 (32.5%)

-

-

0.84

(0.70–1.00.70.00)

0.055

-

-

-

Radiation

No/unknown

2399 (41.4%)

1671 (41.2%)

728 (41.9%)

-

-

-

-

 

Yes

3396 (51.6%)

2385 (58.8%)

1011 (58.1%)

2.27

(1.92–2.67)

< 0.001

2.17

(1.85–2.54)

< 0.001

0.77

Survival time

Median, IQR

2.17

(0.75, 5.25)

2.22

(0.77, 5.27)

2.18

(0.77, 5.28)

-

-

-

-

-

Status

Alive or dead of other disease

4051 (69.9%)

4056 (69.0%)

1739 (71.5%)

-

-

-

-

-

Dead attribute of this carcinoma

1744 (30.1%)

1215 (30.0%)

529 (30.4%)

-

-

-

-

-

  1. 1SCC: squamous cell carcinoma; AC: adenocarcinoma; ACC: adenoid cystic carcinoma; UC: undifferentiated carcinoma; PMM: primary mucosal melanoma.
  2. 2During the imputation process, the limited number of NEC cases (89 cases) resulted in poor convergence of the imputed outcomes. Therefore, in constructing the model, we categorized them as “other.”.
  3. 3the statistical description of the imputed variables is based on the results of merging five imputed datasets using Rubin’s rule. Therefore, the total number can be accurately matched, but for example, the number of individuals at specific stages may not fully correspond, though the values are approximately equivalent.
Back to article page